Join

Compare · DXCM vs TFX

DXCM vs TFX

Side-by-side comparison of DexCom Inc. (DXCM) and Teleflex Incorporated (TFX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and TFX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $28.11B, about 4.9x TFX ($5.75B).
  • Over the past year, DXCM is down 10.2% and TFX is up 7.8% - TFX leads by 18.0 points.
  • DXCM has been more active in the news (26 items in the past 4 weeks vs 15 for TFX).
  • Both have 25 recent analyst ratings on file.
PerformanceDXCM-10.22%TFX+7.76%
2025-06-09+0.00%2026-06-08
MetricDXCMTFX
Company
DexCom Inc.
Teleflex Incorporated
Price
$76.89+5.55%
$132.90+2.50%
Market cap
$28.11B
$5.75B
1M return
+26.19%
+0.80%
1Y return
-10.22%
+7.76%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
2005
News (4w)
26
15
Recent ratings
25
25
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

TFX

Teleflex Incorporated

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Latest DXCM

Latest TFX